4- imino- 1,3- diazabicyclo(3.1.0)hexan- 2- one

08/01/2010 - "Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma."
01/01/2006 - "The current studies compared biological indices of cytotoxicity in 7 human multiple myeloma (MM) cell lines to develop a correlative model for imexon sensitivity. "
01/01/2006 - "Correlates of imexon sensitivity in human multiple myeloma cell lines."
06/01/2001 - "Imexon is a cyanoaziridine derivative that has antitumor activity in multiple myeloma. "
09/15/2000 - "Imexon is an iminopyrrolidone derivative that has selective antitumor activity in multiple myeloma. "

05/01/1992 - "Imexon (4-imino-1, 3-diazabicyclo-(3.1.0)-hexan-2-one) a cyanoaziridine compound was studied in the treatment of the murine retrovirus-induced immunodeficiency disease model of AIDS (LP-BM5, MAIDS). "
01/01/1990 - "Antiviral efficacy of Imexon in the Rauscher murine retrovirus AIDS model."
01/01/1991 - "Imexon and biological response modifiers in murine models of AIDS."

01/01/1991 - "Imexon (4-imino-1,4-diazobicyclo-3.1.0-hexan-2-one) was moderately effective in the treatment of a retroviral infection in a genetically defined murine model. "
01/01/1991 - "Effect of imexon treatment on Friend virus complex infection using genetically defined mice as a model for HIV-1 infection."
01/01/1991 - "Thus it proved to be an effective antiviral agent in this system, although imexon did not completely eliminate retroviral infection in treated mice. "

01/01/2018 - "Patients with measurable, metastatic, treatment-naive pancreatic adenocarcinoma were randomized 1:1 to receive gemcitabine at 1000 mg/m days 1, 8, and 15 with either imexon, 875 mg/m or placebo days 1, 8, and 15 every 28 days. "
01/01/2018 - "The combination of imexon and gemcitabine does not result in improved outcome as initial therapy of metastatic pancreatic adenocarcinoma."
01/01/2018 - "A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma."
07/01/2010 - "Patients with untreated locally advanced or metastatic pancreatic adenocarcinoma received therapy in sequential cohorts on regimen A (n = 19; imexon 200 or 280 mg/m(2) intravenously (IV) over 30 min days 1-5, 15-19 and gemcitabine 800 or 1,000 mg/m(2) IV over 30 min on days 1,8,15 every 28 days) or regimen B (n = 86; imexon 280-1,300 mg/m(2) IV over 30-60 min days 1, 8, and 15 and gemcitabine 1,000 mg/m(2) IV over 30 min on days 1, 8, and 15 every 28 days). "

11/01/2009 - "Imexon is already in clinical trials in patients with advanced solid tumors. "
05/01/2007 - "The purpose of this trial was to define the maximum-tolerated dose (MTD), toxicities, pharmacokinetics, and pharmacodynamics of imexon in patients with advanced cancers. "
05/01/2007 - "Phase I trial of imexon in patients with advanced malignancy."
05/01/2007 - "This study evaluated the cytotoxic effects of imexon (NSC-714597) in tumor cells when combined with a broad panel of chemotherapeutic drugs. "
05/01/2007 - "Forty-nine patients with metastatic cancer received intravenous imexon over 30 to 45 minutes for 5 consecutive days (one course) every other week (days 1 through 5 and 15 through 19) monthly. "